Codiak BioSciences, Inc. reports results for the quarter ended in March - Earnings Summary

Codiak BioSciences,.

07/05/2021 24:00

* Codiak BioSciences, Inc.  CDAK.OQ  reported a quarterly
adjusted loss of 51 cents​​ per share for the quarter ended
in March. The mean expectation of three analysts for the quarter
was for a loss of $1.09 per share.
* Revenue was $13.19 million​​;  analysts expected $966.00
thousand.
* Codiak BioSciences, Inc.'s reported EPS for the quarter was a
loss of 51 cents​.
* The mean earnings estimate of analysts had risen by about 5.2%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Codiak BioSciences, Inc. shares had risen by 33.2% this
quarter and lost 37.8% so far this year.
* The company reported a quarterly loss of $10.31 million.
* Wall Street's median 12-month price target for Codiak
BioSciences, Inc. is $34.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 11:00 p.m. GMT. ​All
figures in US Dollars.​